Recipharm appoints President Development Services to drive end to end offering
Contract development and manufacturing organisation (CDMO) Recipharm has appointed Bernard Pluta to lead its new global development organisation.
The newly established position forms part of the ongoing transformation of Recipharm’s Development Services, in which a total of 400 employees across six countries are united to deliver a comprehensive development offering.
The scientific, chemical and pharmaceutical expertise will cover end to end development services, ranging from development of the active compound to providing dossiers for marketing authorisation applications in all major geographies. The combined capabilities and capacities will provide the CDMO’s customers with an efficient pathway to commercialisation.
Bernard Pluta is currently the General Manager of Recipharm’s manufacturing and development operations in Pessac, France and recently led a Group wide project focusing on optimising and coordinating Recipharm’s extensive development capacities in Sweden, Italy, France, US, India and Israel.
Thomas Eldered said: “I am delighted to announce the appointment of Bernard Pluta as President, Development Services. Bernard has managed our operations in Pessac with great success. His industry expertise and solid business competence will play a key role in transforming our development services and ensuring a seamless end to end offering. By providing a wide range of development services we are well positioned to manage challenging projects and complexity on behalf of our customers.”
Bernard Pluta has strong experience in the pharma and CDMO industry having held executive positions with Theramex, Merck Serono and Teva. He also ran his own CMO consultancy business before joining Recipharm in 2015 and he holds a dual degree as Industrial Engineer and MBA. In his role as President, Development Services, Bernard Pluta will report to CEO Thomas Eldered and be a part of the Group management team. Bernard will continue as General Manager of Recipharm in Pessac until a successor has been appointed.
Recipharm’s new development organisation will be implemented during the first half of 2018. Development services will continue to be reported as part of Recipharm’s Development & Technology segment.
Thomas Eldered, CEO, telephone: +46 8 602 52 10
Henrik Stenqvist, CFO, email@example.com, telephone: +46 8 602 52 00
This information is information that Recipharm AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on 14 February 2018, at 11:30 CET.
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing around 5,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 5.3 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com.